All In Biotech

Drug Trial Radar · NCT01732926

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 475 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

475

Actual

Start

Jan 2, 2013

Primary completion

May 17, 2016

Study completion May 17, 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL). An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

Conditions

  • Indolent Non-Hodgkin's Lymphomas

Interventions

  • IdelalisibDrug

    150 mg tablet administered orally twice daily

  • RituximabDrug

    375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)

  • BendamustineDrug

    90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)

  • PlaceboDrug

    Tablet administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)

Locations

144 sites in 15 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Ironwood Cancer and Research Center

    Chandler, Arizona

  • Comprehensive Blood and Cancer Center (Bakersfield)

    Bakersfield, California

  • Saint Jude Heritage Healthcare (TORI)

    Fullerton, California

  • Pacific Shores Medical Group

    Long Beach, California

  • Cancer Care Associates

    Redondo Beach, California

  • San Luis Obispo Oncology and Hematology

    San Luis Obispo, California

  • Cancer Center of Santa Barbara

    Santa Barbara, California

  • Central Coast Medical Oncology Group

    Santa Maria, California

  • St Joseph Heritage Healthcare System

    Santa Rosa, California

  • Kaiser Permanente Vallejo Medical Center

    Vallejo, California

  • Sylvester Comprehensive Cancer Center/UMHC

    Deerfield Beach, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Northwest Georgia Oncology Centers, PC

    Marietta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Joliet Oncology Hematology Associates Ltd.

    Joliet, Illinois

  • Cancer Center of Kansas

    Wichita, Kansas

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • North Shore Hematology/Oncology Associates

    East Setauket, New York

  • Weill Cornell Medical College

    New York, New York

  • Signal Point Clinical Research Center, LLC

    Middletown, Ohio

  • Hollings Cancer Center

    Charleston, South Carolina

  • Bon Secours Saint Francis Hospital

    Greenville, South Carolina

  • Texas Oncology, P.A.

    Bedford, Texas

  • Charles A. Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology, P.A.

    Denton, Texas

  • Brooke Army Medical Center

    Fort Sam Houston, Texas

  • Texas Oncology, P.A.

    Harlingen, Texas

  • Texas Oncology, P.A.

    Weslaco, Texas

  • Swedish Medical Center

    Seattle, Washington

  • Northwest Medical Specialists

    Tacoma, Washington

  • Aurora BayCare Medical Center

    Green Bay, Wisconsin

  • Froedtert Hospital and Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Haematology and Oncology Clinics of Australia Gold Coast

    South Brisbane, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Adelaide Cancer Centre

    Kurralta Park, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Saint Vincent's Hospital

    Fitzroy, Victoria, Australia

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.